Innoventric, a New York-based company pioneering in cardiac care, has raised $28.5 million in a Series B funding round to advance its innovative treatment for tricuspid regurgitation (TR), a serious heart condition. The funding will fuel clinical trials and regulatory approvals in the U.S. and Europe.
- Funding Round: Series B round raised $28.5 million, led by RA Capital Management, with European Investment Committee (EIC), BRM Group, JG Private Equity, and Mivtach Shamir Holdings.
- Funding Goals: Innoventric will use the funds to push clinical trials forward and seek regulatory approvals across the U.S. and Europe.
- Innoventric’s Technology: Led by CEO Amir Danino, Innoventric developed a device to treat tricuspid regurgitation by anchoring a prosthetic valve to the vena cava rather than the moving heart.
- Device Advantages: Broad Patient Accessibility, Secure Anchoring, and Efficient Implantation.
With strong backing from RA Capital Management and key European investors, Innoventric is on track to redefine tricuspid valve treatment, making life-saving care more accessible for patients worldwide.
